CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Cash flows from operating activities:
Net income (loss)	$ 31,712	$ (13,821)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Adjustment for income from EIR method purchased receivables	(5,925)	(15,066)
Stock-based compensation expense	9,273	10,312
Gains on acquisitions	(21,224)	(19,316)
Credit losses on purchased receivables		30,904
Gain on sale of equity securities	(3,663)
Income tax expense (benefit)	103	(5,658)
Common stock contribution to 401(k)	141	118
Amortization of intangible assets	2,961	206
Depreciation	11	10
Accretion of long-term debt discount and debt issuance costs	1,385	1,350
Non-cash lease expense	64	60
Change in fair value of equity securities	(90)	(131)
Change in fair value of available-for-sale debt securities classified as cash equivalents	(20)	73
Change in fair value of derivatives	(93)
CVR liability working capital adjustment	(394)
Changes in assets and liabilities:
Trade and other receivables, net	(2,426)	(835)
Prepaid expenses and other assets	3,839	302
Accounts payable and accrued liabilities	(10,597)	1,598
Operating lease liabilities	(876)	(284)
Unearned revenue recognized under units-of-revenue method	(1,310)	(3,570)
Net cash provided by (used in) operating activities	2,871	(13,748)
Cash flows from investing activities:
Payments of consideration under RPAs, AAAs, and CPPAs	(8,000)	(53,000)
Receipts under RPAs, AAAs, and CPPAs	3,300	29,248
Net payment for IP acquired under the Pulmokine Acquisition		(20,176)
Payment for BioInvent contract-based intangible asset	(20,725)
Payment of contingent consideration related to Kinnate IP asset	(550)
Purchase of property and equipment		(20)
Purchase of equity securities	(99)	(3,237)
Sale of equity securities	6,999
Payment to issue short-term loan to Xeno	(5,877)
Receipt from short-term loan repayment by Xeno	5,877
Net cash provided by (used in) investing activities	50,886	(28,259)
Cash flows from financing activities:
Proceeds from issuance of common stock	323
Proceeds from issuance of preferred stock	4,019
Payments of preferred and common stock issuance and financing costs	(672)
Principal payments - debt	(10,598)	(6,902)
Debt issuance costs and loan fees paid in connection with long-term debt	(80)	(740)
Payment of preferred stock dividends	(5,472)	(5,472)
Repurchases of common stock	(16,043)	(13)
Proceeds from exercise of options and other share-based compensation	5,046	5,214
Taxes paid related to net share settlement of equity awards	(2,986)	(3,214)
Net cash used in financing activities	(26,463)	(11,127)
Net increase (decrease) in cash, cash equivalents, and restricted cash	27,294	(53,134)
Cash, cash equivalents, and restricted cash as of the beginning of the period	106,416	159,550
Cash, cash equivalents, and restricted cash as of the end of the period	133,710	106,416
Supplemental cash flow information:
Cash paid for interest	11,906	9,985
Cash paid for taxes	277
Non-cash investing and financing activities:
Excise tax accrual due to stock repurchases	68
Reclassification of equity classified awards to liabilities	(739)
Reclassification of deferred issuance cost to equity	578
Preferred stock dividend accrual	1,424	1,368
Estimated fair value of the Exarafenib milestone asset		2,922
Estimated fair value of the Exarafenib milestone contingent consideration		(2,922)
Accrual of contingent consideration under the Affitech CPPA		3,000
Accrual of contingent consideration under the LadRx AAA		1,000
Turnstone
Cash flows from investing activities:
Net cash acquired in acquisition	3,850
Non-cash investing and financing activities:
Accrual of contingent value rights liability in the acquisition	1,110
HilleVax
Cash flows from investing activities:
Net cash and restricted cash acquired in acquisition	46,384
Non-cash investing and financing activities:
Accrual of contingent value rights liability in the acquisition	5,673
Right-of-use assets obtained in exchange for operating lease liabilities in the acquisition	22,525
Relative fair value basis reduction of rights-of-use assets in the acquisition	(22,525)
Kinnate
Cash flows from investing activities:
Net cash acquired in acquisition		18,926
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities in the acquisition		824
Relative fair value basis reduction of rights-of-use assets in the acquisition		$ (824)
LAVA
Cash flows from investing activities:
Net cash and restricted cash acquired in acquisition	15,263
Non-cash investing and financing activities:
Accrual of contingent value rights liability in the acquisition	9,114
Mural
Cash flows from investing activities:
Net cash and restricted cash acquired in acquisition	4,464
Non-cash investing and financing activities:
Transaction costs in connection with acquisition included in accrued expenses	$ 320